Evercore ISI downgraded Avantor to In Line from Outperform with a price target of $21, down from $22. All of the life science tools companies who have reported Q2 results so far this earnings season, including Avantor, have missed and lowered guidance, the analyst tells investors. The analyst will be removing Avantor from Evercore ISI’s Best “Core” Ideas list, the firm noted.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on AVTR: